Pharmacological interventions for peripartum cardiomyopathy

Michail Papapanou; Dennis Vaidakis; Themistoklis Paraskevas; Theodoros N Sergentanis; Charalampos S Siristatidis

doi:10.1002/14651858.CD014851

Pharmacological interventions for peripartum cardiomyopathy

Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD014851. doi: 10.1002/14651858.CD014851.

Authors

Michail Papapanou^{1

2}, Dennis Vaidakis³, Themistoklis Paraskevas⁴, Theodoros N Sergentanis⁵, Charalampos S Siristatidis⁶

Affiliations

¹ Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
² Obstetrics, Gynecology and Reproductive Medicine Working Group, Society of Junior Doctors, Athens, Greece.
³ Department of Basic and Clinical Sciences, University of Nicosia, Medical school, Nicosia, Cyprus.
⁴ Department of Internal Medicine, University General Hospital of Patras, Patras, Greece.
⁵ Department of Public Health Policy, School of Public Health, University of West Attica, Aigaleo, Greece.
⁶ Assisted Reproduction Unit, 2nd Department of Obstetrics and Gynaecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of available pharmacological interventions for the care of women diagnosed with PPCM.

MeSH terms

Cardiomyopathies / drug therapy
Female
Humans
Peripartum Period
Pregnancy
Pregnancy Complications, Cardiovascular* / drug therapy
Puerperal Disorders / drug therapy
Randomized Controlled Trials as Topic